Samsung Asset Management New York Inc. cut its position in shares of Amgen Inc. (NASDAQ:AMGN) by 42.7% during the second quarter, Holdings Channel reports. The firm owned 6,750 shares of the medical research company’s stock after selling 5,040 shares during the period. Samsung Asset Management New York Inc.’s holdings in Amgen were worth $1,027,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of AMGN. Oak Associates Ltd. OH increased its position in shares of Amgen by 0.3% in the first quarter. Oak Associates Ltd. OH now owns 210,710 shares of the medical research company’s stock worth $31,592,000 after buying an additional 581 shares in the last quarter. National Pension Service increased its position in shares of Amgen by 4.2% in the first quarter. National Pension Service now owns 378,322 shares of the medical research company’s stock worth $56,722,000 after buying an additional 15,376 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Amgen by 2.1% in the first quarter. Geode Capital Management LLC now owns 6,444,273 shares of the medical research company’s stock worth $964,334,000 after buying an additional 132,632 shares in the last quarter. Prudential PLC increased its position in shares of Amgen by 41.4% in the first quarter. Prudential PLC now owns 1,062,893 shares of the medical research company’s stock worth $159,359,000 after buying an additional 311,157 shares in the last quarter. Finally, Legal & General Group Plc increased its position in shares of Amgen by 1.0% in the first quarter. Legal & General Group Plc now owns 3,263,086 shares of the medical research company’s stock worth $489,239,000 after buying an additional 32,086 shares in the last quarter. Institutional investors and hedge funds own 79.15% of the company’s stock.
Amgen Inc. (NASDAQ:AMGN) traded down 0.89% during midday trading on Monday, hitting $173.24. The stock had a trading volume of 539,475 shares. The stock’s 50-day moving average is $172.09 and its 200-day moving average is $160.08. The company has a market cap of $129.65 billion, a P/E ratio of 17.73 and a beta of 0.87. Amgen Inc. has a one year low of $130.09 and a one year high of $176.85.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Wednesday, July 27th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.74 by $0.10. Amgen had a net margin of 33.07% and a return on equity of 29.30%. The company had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.58 billion. During the same quarter in the previous year, the firm posted $2.57 earnings per share. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. Equities analysts predict that Amgen Inc. will post $11.36 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Thursday, September 8th. Stockholders of record on Wednesday, August 17th were given a $1.00 dividend. This represents a $4.00 annualized dividend and a dividend yield of 2.29%. The ex-dividend date of this dividend was Monday, August 15th. Amgen’s dividend payout ratio (DPR) is currently 40.90%.
A number of brokerages recently commented on AMGN. Jefferies Group increased their price target on Amgen from $187.00 to $198.00 and gave the company a “buy” rating in a report on Thursday, July 28th. Zacks Investment Research raised Amgen from a “hold” rating to a “buy” rating and set a $166.00 target price on the stock in a report on Wednesday, June 29th. Vetr raised Amgen from a “hold” rating to a “buy” rating and set a $159.50 target price on the stock in a report on Monday, June 13th. Leerink Swann reaffirmed a “hold” rating on shares of Amgen in a report on Sunday, June 26th. Finally, Argus reaffirmed a “buy” rating and set a $195.00 target price (up previously from $185.00) on shares of Amgen in a report on Friday, August 5th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $184.56.
In other news, VP Annette Louise Such sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 2nd. The shares were sold at an average price of $174.59, for a total value of $523,770.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.20% of the stock is currently owned by insiders.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.